Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Ionis Pharmaceuticals IONS shares rallied 8.9% in the last trading session to close at $27.77. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Ionis Pharmaceuticals stock opened at $28.40 on Friday. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. The company has a market capitalization ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $59.00.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high estimate of $70.00 and a low estimate of $39.00. Observing a downward ...

CARLSBAD, Calif., April 16, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 a.m. Eastern Time to discuss its ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 ...

Ionis Pharmaceuticals IONS shares rallied 8.9% in the last trading session to close at $27.77. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...